Gruenenthal Gmbh

Grunenthal Gmbh

Dagmar Kaulartz

Klaus Schiene

Helmut Heinrich Buschmann

Gregor Bahrenberg

Achim Kless

Sven Kuehnert

Carsten Griebel

Bernd Sundermann

Werner Guenter Englberger

Babette-Yvonne Koegel

Hagen-Heinrich Hennies

Thomas Christoph

Stefan Oberboersch

Ruth Jostock

Elmar Josef Friderichs

Corinna Sundermann

Robert Frank

Beatrix Merla

Oswald K Zimmer

Wolfgang Schröder

Michael Haurand

Derek John Saunders

Sven Kühnert

Saskia Zemolka

Petra Bloms-Funke

Wolfgang Schroeder

Claudia Katharina Puetz

Ivars Graudums

Thomas Tzschentke

Stefan Oberbörsch

Sabine Reinardy

Hans-Joachim Gais

The invention relates to substituted 2-amino-quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators

Substituted nicotinamide compounds corresponding to formula I a process for their preparation, pharmaceutical compositions containing these compounds, and the use thereof for the treatment or inhibition conditions such as pain, epilepsy, migraine, anxiety states, or urinary incontinence.

Substituted nicotinamide compounds and uses thereof

Substituted bicyclic imidazo-3-yl-amine compounds are provided, as well as processes for the production thereof and pharmaceutical formulations containing these compounds. The use of these compounds for the production of pharmaceutical formulations and related methods of treatment are also provided.

Substituted bicyclic imidazo-3-ylamine compounds

Saturated and unsaturated heteroarylcycloalkylmethyl-amine compounds corresponding to formula I, processes for their preparation, pharmaceutical formulations comprising these compounds and the use of saturated and unsaturated heteroarylcycloalkylmethyl-amines for the preparation of pharmaceutical formulations. pharmaceutical formulations and related methods of treatment or prophylaxis of certain condition, especially depression and/or pain, are also disclosed.

Saturated and unsaturated heteroarylcycloalkylmethyl amines as anti-depressants

The invention relates to a process for the enzymatic cleavage of racemates of aminomethyl-aryl-cyclohexanol derivatives.

Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives

The invention relates to O-substituted 6-methyl-tramadol derivatives, to methods for producing them, to medicaments containing these compounds, to the use of O-substituted 6-methyl-tramadol derivatives for producing medicaments for treating pain and other symptoms or diseases, and to methods of treatment using the medicaments.

O-substituted 6-methyltramadol derivatives

Growing community of inventors

Stolberg, Germany

Dagmar Kaulartz